Press coverage about OncoGenex Pharmaceuticals (NASDAQ:ACHV) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a news impact score of 0.21 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.9828633713314 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) traded up 0.88% during mid-day trading on Tuesday, reaching $2.28. The company’s stock had a trading volume of 15,135 shares. OncoGenex Pharmaceuticals has a one year low of $2.19 and a one year high of $10.18. The stock’s market cap is $24.96 million. The firm’s 50 day moving average is $3.01 and its 200-day moving average is $1.07.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter.

Separately, ValuEngine raised OncoGenex Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact OncoGenex Pharmaceuticals (ACHV) Share Price” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at

OncoGenex Pharmaceuticals Company Profile

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.